Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently…
Consensus price target: $490.00 (+28723.53% upside from $1.70)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Scilex Holding Co 10 percent owner | Dec 30, 2025 | Sale | 9,657,300 | $5.21M |
| Scilex Holding Co 10 percent owner | Dec 29, 2025 | Sale | 7,310,984 | $4.79M |
| Scilex Holding Co 10 percent owner | Dec 26, 2025 | Sale | 3,689,016 | $2.77M |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $30.25M | -46.54% | $-358.73M |
| 2024 | $56.59M | +21.07% | $-72.81M |
| 2023 | $46.74M | +22.9% | $-114.33M |
Stock data for SCLX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics